The lead programme, RPL554, is an innovative dual phosphodiesterase (PDE) 3 and 4 inhibitor with both bronchodilator
and anti-inflammatory properties.
As reported on 29 September 2015, Phase IIa results from a prior study using nebulised RPL554 alone in stable COPD patients with moderate severity of disease, showed that, in addition to good tolerability and safety profile, RPL554 caused a pronounced improvement in lung function, as measured by peak FEV1, suggesting the drug produced a clinically meaningful bronchodilator
- Product Analysis, Market Data & Forecasts
In contrast, there is also a concern that because asthma is a potentially life-threatening condition that should be diagnosed and treated by a health care professional, availability of an OTC bronchodilator
product may discourage consumers from seeking appropriate care, resulting in worse asthma outcomes.
Significantly increased risks were noted for any bronchodilator
use (without an additional anti-inflammatory drug) and cleft lip alone (adjusted odds ratio, 1.
Earlier this year the FDA released a number of bronchodilators
that will be phased out due to the use of chlorofluorocarbons (CFC).
Key words: COPD, COPD management, smoking cessation, inhaled corticosteroids, tiotropium, long-acting beta-2 agonists, short acting bronchodilators
, pulmonary rehabilitation.
In patients with persistent symptoms it is preferable to use long-acting bronchodilators
xx in primary or secondary positions) between January 1998 and December 2004, (2) had regular treatment with inhaled bronchodilators
(defined by at least three pharmacy claims of anticholinergics or long-acting [[beta].
Side effects of bronchodilators
can include nervousness, shakiness, and a rapid heart rate.
But there are treatments, including bronchodilators
or inhalers, which widen breathing passages to help stop asthma attacks.
The new findings add to the growing unease about relying on bronchodilators
as standard treatment.
For people who have mild or infrequent attacks, inhalers containing bronchodilators
(such as Proventil, Ventolin, Alupent, and Metaprel) are widely prescribed and have proved in most cases to be very useful.
The market is segmented by mechanisms of action: anti-inflammatories, bronchodilators
, and combination therapies.
The primary objective of this study is to evaluate whether RPL554 has an additive bronchodilator
effect in COPD patients, when administered in addition to standard of care bronchodilators